

# 3C study

<https://neurodegenerationresearch.eu/survey/3c-study/>

## **Title of cohort**

3C study

## **Acronym for cohort**

3C

## **Name of Principal Investigator - Title**

Prof

## **Name of Principal Investigator - First name**

Christophe

## **Name of Principal Investigator - Last name**

Tzourio

## **Address of institution -Institution**

INSERM - U1219

## **Address of institution - Street address**

146 rue Léo-Saignat

## **Address of institution - City**

Bordeaux Cedex

## **Address of institution - Postcode**

33076

## **Country**

France

## **Website**

<http://www.three-city-study.com/>

## **Contact email**

## **Funding source**

Inserm, CNRS, universités, MGEN, CNAM-TS, ISPED, DGS, GIS Institut de longévité, FDF, Conseils régionaux d'Aquitaine et de Bourgogne, Ministère chargé de la recherche, Agence

**Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions?**

Alzheimer's disease and other dementias

**Q1b. When are studies on the above condition(s) expected to become possible?**

Already possible

**Q2a. In a single sentence what is the stated aim of the cohort?**

Study the impact of vascular factors on dementia risk in the over 65 population.

**Q2b. What distinguishes this cohort from other population cohorts?**

**Q3a. i) Number of publications that involve use of your cohort to date**

372

**Q3a.ii) Please give up to three examples of studies to date (Principal Investigator, Institution, Title of Study)**

**Q3b. If data on research outputs are already available please paste the publication list/other data or provide a link to where these data are publicly available**

<http://www.three-city-study.com/publications.php>

**Q3c. If no research has been done as yet, please explain in a few sentences what information (i.e. research findings) you expect will be gained from the population**

**Q4a. Study criteria: what is the age range of participants at recruitment? Age in years From:**

65

**Q4a. Study criteria: what is the age range of participants at recruitment? To:**

until death

**Q4b. Study criteria: what are the inclusion criteria?**

65 or more years old subjects, inscribed on the electoral lists, and having a phone

**Q4c. Study criteria: what are the exclusion criteria?**

None

**Q5. What is the size of the cohort (i.e. how many participants have enrolled)?**

5,001-10,000 participants

**Q6a. Please describe what measures are used to characterise participants**

medical examination, psychometric tests

**Q6b. Are there additional measures for participants with a clinical disorder?**

Additional psychometric tests

**Q6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)?**

No

**If yes please specify**

**Q7. What is the study design (select all that apply)?**

Prospective cohort|Longitudinal

**Q8. Are your cases matched by**

**Q9a. Does your study include a specialised subset of control participants?**

No

**Q9b. If your study includes a specialised subset of control participants please describe**

**Q10a. i) Please enter the data collection start date**

01/01/1999

**Q10a. ii) Please enter the data collection end date**

01/01/2016

**Q10a. iii) Is data collection for this study**

Data analysis ongoing

**Q10b. If data collection is ongoing, are there plans to continue the cohort study beyond the current projected end date?**

Yes - funding applied for/funding awarded

**Q11. Is data collected**

Through links to medical records

**Other please specify here**

CNAMTS, PMSI

**Q12. Is there a system in place to enable re-contact with patients to ask about participation in future studies?**

No

**Q13a. Please give information on the format and availability of data stored in a database (1)**

Data summarised in database

**% available**

100

**Q13a. Please give information on the format and availability of data stored in a database (2)**

Database is web-based

**% available**

100

**Q13a. Please give information on the format and availability of data stored in a database (3)**

No

**% available**

**Q13a. Please give information on the format and availability of data stored in a database (4)**

No

**% available**

**Other (please specify)**

**% available**

**Q13b. Please give information on the format and availability of data held as individual records (1)**

Data is held as individual records

**% available**

**Q13b. Please give information on the format and availability of data held as individual records (2)**

No

% available

**Q13b. Please give information on the format and availability of data held as individual records (3)**

No

% available

**Q13b. Please give information on the format and availability of data held as individual records (4)**

No

% available

**Please specify language used**

**Q14a. Is data available to other groups?**

Yes

**Q14b. If data is available to other groups what is the access policy/mechanisms for access?**

Apply to PI or co-ordinator at resource| Access committee mechanism| Access committee mechanism| National access| International access| Access to industry

**Q15. What data sharing policy is specified as a condition of use?**

Data made publicly available after a specified time point

**Q16a. Are tissues/samples/DNA available to other groups?**

Yes

**Q16b i) If yes, please describe below:**

Living donors blood| Living donors: blood derivatives| Living donors: DNA

**Q16b. ii) In what form are tissues/samples/DNA supplied?**

Primary Samples: Stabilised samples (frozen or fixed)

**Q16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data (Q14 above)?**

Yes

**Q17. Is information on biological characteristics available to other groups?**

Yes, for all the cohort

**Number of Patients**  
**% of total cohort**

**Types:**

Population Cohorts

**Member States:**

France

**Diseases:**

Alzheimer's disease & other dementias

**Years:**

2016

**Database Categories:**

N/A

**Database Tags:**

N/A